Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 14, 2018

Primary Completion Date

January 2, 2020

Study Completion Date

January 2, 2020

Conditions
Psychiatric Disorder
Interventions
GENETIC

Pharmacogentic Analysis

Participant will complete a buccal swab and it will be sent off to OneOme for analysis. When the results are available, the study investigators will review the medications for potential drug-drug and drug-genotype interactions. The risk for interactions will be classified as low, medium or high. The investigators will then communicate to the clinical team taking care of the patient these results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER